The global cell culture media market is projected to reach USD 13.0 billion by 2028 from USD 6.2 billion in 2023, at a CAGR of 16.0% during the forecast period. The major factors uplifting the market emerging cell culture technologies for cell-based vaccines, increasing demand for monoclonal antibodies and biosimilars, increased investment in stem cell research. Furthermore, launch of novel cell culture media by market players, increasing demand for serum and animal component-free media and the growing focus on personalized medicine are some of the major elements anticipated to drive the growth of the market.
The global cell culture media market is consolidated, with large, medium-sized, and small market players. The global cell culture media market was dominated by Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Sartorius AG (Germany), Corning Incorporated (US), FUJIFILM Irvine Scientific, Inc. (Japan), Lonza Group AG (Switzerland), Becton, Dickinson and Company (US) and among others
To know about the assumptions considered for the study download the pdf brochure
Thermo Fisher Scientific, Inc. (US)
The company provides cell culture products, including cell culture media, through its life sciences solutions and specialty diagnostics segments. The company has a strong geographic footprint and operates in more than 170 countries across North America, Europe, Latin America, and Asia. In recent years, In 2022, the company invested USD 1.47 billion in the R&D of new products to cater to the unmet needs in the healthcare industry. This increasing R&D helped Thermo Fisher to launch new products in this market. For instance, in June 2023, the company launched Tumoroid Culture Medium to accelerate development of novel cancer therapies. With its strong product portfolio, continuous research and development activities, and broad geographic reach, Thermo Fisher Scientific is expected to witness significant growth in the market.
Merck KGaA (Germany)
Merck KGaA is one of the leading players in the cell culture media market. Its key strength lies in its strong product portfolio. Owing to the unsurpassed quality and consistent results the company’s products provide, many researchers specify Merck instruments when conducting experiments. The company adopts organic growth strategies to increase its dominance in this market. Merck invests substantially in R&D to provide innovative products. In 2022, the company invested USD 2.66 billion in R&D. With its strong R&D capabilities and increasing geographical presence, the company is expected to maintain its leading position in the market. Merck focuses on in-house research and external partnerships in its R&D operations, maximizing its research efficiency while reducing financial outlays. In the Life Science business sector, the company’s research activities focused on laboratory and life science applications
Danaher Corporation (US)
Danaher is a prominent player in the cell culture media market owing to its strong portfolio of media products. The company conducts its business through three segments, namely, Life Sciences, Diagnostics, and Environmental & Applied Solutions. The company has a strong geographic presence with subsidiaries across North America, Europe, the Asia Pacific, Latin America, and Africa. This increase can be attributed to the strategic acquisitions and collaborations undertaken by the company. For instance, in January 2022, Cytiva and Nucleus Biologics LLC collaborated to enhance custom cell media development for cell and gene therapies.
Cell Culture Media Market by Type(Serum-free (CHO, BHK, Vero Cell), Stem Cell, Chemically Defined, Classical, Specialty), Application(Biopharmaceutical (mAbs, Vaccine), Diagnostics, Tissue Engineering), End User(Pharma, Biotech) - Global Forecast to 2028
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE